The Evolving Role of PCSK9 Inhibitors in LDL-C Management

In this episode of CardiaCast, Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals. They discuss available PCSK9 inhibitors, including the recently approved injectable PCSK9 inhibitor lerodalcibep-liga. After discussing the limitations and barriers associated with injectable PCSK9 inhibitors, they will introduce the emerging oral PCSK9 inhibitors and explore the latest clinical data for enlicitide and AZD0780.

This podcast was developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Merck.